Rivastigmine transdermal system receives FDA approval for Alzheimer's disease

被引：0

|

作者：

Ralat, Jose

机构：

来源：

CNS SPECTRUMS | 2007年 / 12卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：581 / 582

页数：2

相关论文

共 50 条

[1] Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease
Nieto, Rachel A.
Deardorff, William James
Grossberg, George T.
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (06) : 861 - 870
[2] Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease
Grossberg, G. T.
Sadowsky, C.
Olin, J. T.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) : 651 - 660
[3] Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease
Winblad, Bengt
Machado, Joao Carlos
EXPERT OPINION ON DRUG DELIVERY, 2008, 5 (12) : 1377 - 1386
[4] Morbus Alzheimer - Rivastigmine: Approval for the first transdermal application granted in Europe
不详
NERVENARZT, 2007, 78 (10): : A1 - A3
[5] Transdermal rivastigmine for Alzheimer's disease: skin deep or scratching the surface?
Larner, A. J.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) : 534 - 536
[6] Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions
Amanatkar, Hamid Reza
Grossberg, George Thomas
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (10) : 1119 - 1125
[7] Efavirenz receives FDA approval
Dobkin, JF
INFECTIONS IN MEDICINE, 1998, 15 (11) : 747 - 747
[8] The Aveir Leadless Pacing System receives FDA approval
Han, Jason J.
ARTIFICIAL ORGANS, 2022, 46 (07) : 1219 - 1220
[9] Zelboraf Receives FDA Approval
不详
JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (10) : 1215 - 1215
[10] Watson's Generic Lidoderm® Receives FDA Approval
不详
JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (10) : 1249 - 1249

← 1 2 3 4 5 →